GENTA INCORPORATED /DE/
NT 10-K, 1999-04-01
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: VERTEL CORP, S-8, 1999-04-01
Next: GENTA INCORPORATED /DE/, PRE 14C, 1999-04-01




                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 12b-25
                                              Commission File Number 0-19635
                                                                     -------

                           NOTIFICATION OF LATE FILING

(Check One):   [X|  Form 10-K  |_| Form 11-K  |_| Form 20-F  |_| Form 10-Q
               |_|  Form N-SAR

               For Period Ended: December 31, 1998
               [ ] Transition Report on Form 10-K 
               [ ] Transition Report on Form 20-F 
               [ ] Transition Report on Form 11-K 
               [ ] Transition Report on Form 10-Q 
               [ ] Transition Report on Form N-SAR
               For the Transition Period Ended:
                                                  ------------------------------

- --------------------------------------------------------------------------------
             Read instruction before preparing form. Please print or type.

Nothing in this form shall be construed  to imply that the  Commission has
verified any information contained herein.
- --------------------------------------------------------------------------------

If the notification  relates to a portion of the filing checked above,  identify
the item(s) to which the notification relates:

- --------------------------------------------------------------------------------

PART I - REGISTRANT INFORMATION

     Genta Incorporated
- --------------------------------------------------------------------------------
Full Name of Registrant

- --------------------------------------------------------------------------------
Former Name if Applicable

     3550 General Atomics Court
- ------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)

     San Diego, CA 92121
- ------------------------------------------------------------------------------
City, State and Zip Code

PART II -- RULE 12b-25(b) AND (c)

If the subject report could not be filed without  unreasonable effort or expense
and the  registrant  seeks  relief  pursuant to Rule 12b- 25(b),  the  following
should be completed. (Check box if appropriate)

      [x]  (a) The reasons  described  in  reasonable  detail in Part III of
               this form could not be eliminated without  unreasonable effort or
               expense;

      [x]  (b) The subject annual  report,  semi-annual  report,  transition
               report on Form 10-K,  Form 20-F,  11-K or Form N-SAR,  or portion
               thereof,  will be filed on or before the  fifteenth  calendar day
               following  the  prescribed  due date;  or the  subject  quarterly
               report or transition report on Form 10-Q, or portion thereof will
               be filed on or  before  the  fifth  calendar  day  following  the
               prescribed due date; and

      [ ] (c)  The  accountant's  statement  or other  exhibit  required  by 
               Rule 12b-25(c) has been attached if applicable.


<PAGE>


PART III -- NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q,
N-SAR, or the transition report portion thereof could not be filed within the
prescribed time period. (Attach Extra Sheets if Needed) 

See Attachment I

PART IV -- OTHER INFORMATION

(1)    Name and telephone number of person to contact in regard to this 
       notification

           Kenneth G. Kasses, Ph.D.              (781)            402-3450
       -------------------------------    ------------------- -----------------
                            (Name)             (Area Code)   (Telephone Number)

(2)     Have all other  periodic  reports  required under Section 13 or 15(d) of
        the  Securities  Exchange  Act of 1934 or Section  30 of the  Investment
        Company Act of 1940 during the  preceding  12 months or for such shorter
        period that the  registrant  was  required to file such  report(s)  been
        filed? If the answer is no, 
        identify report(s).                                      |X| Yes |_| No

- -------------------------------------------------------------------------------

(3)     Is it anticipated  that any significant  change in results of operations
        from the corresponding period for the last fiscal year will be reflected
        by the  earnings  statements  to be included  in the  subject  report or
        portion thereof?                                         |X| Yes |_| No

        If so, attach an explanation of the anticipated change, both narratively
        and  quantitatively,  and,  if  appropriate,  state  the  reasons  why a
        reasonable estimate of the results cannot be made.

                      See Attachment II
- -------------------------------------------------------------------------------

                               Genta Incorporated
          -------------------------------------------------------
                  (Name of Registrant as Specified in Charter)

Has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.


Date     March 31, 1999              By   /s/ Kenneth G. Kasses  
    -----------------------------    ---------------------------------------
                                          Kenneth G. Kasses, Ph.D.
                                          President, Chief Executive Officer and
                                          Chairman of the Board of Directors

INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly  authorized  representative.  The name and title of the person
signing  the form  shall  be typed or  printed  beneath  the  signature.  If the
statement is signed on behalf of the registrant by an authorized  representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

                                    ATTENTION
- -------------------------------------------------------------------------------
   Intentional misstatements or omissions of fact constitute Federal criminal
                        violations (See 18 U.S.C. 1001).
- -------------------------------------------------------------------------------


<PAGE>


                       Genta Incorporated (the "Company")
                                   Form 12b-25
        Annual Report on Form 10-K for the Period Ended December 31, 1998


                                  Attachment I


        The  Company is not able to file its Annual  Report on Form 10-K for the
period ended December 31, 1998 (the "Annual  Report") within the prescribed time
period without  unreasonable  effort or expense. In a Form 8-K filed on November
3, 1998, the Company disclosed that its previous independent  auditors,  Ernst &
Young LLP ("E&Y"),  had resigned.  In a Form 8-K filed on February 12, 1999, the
Company  further  disclosed  that the  Company  had hired  Deloitte & Touche LLP
("D&T") as the  Company's new  independent  auditors.  In addition,  the Company
hired a  Chief  Financial  Officer  (also  the  Company's  Principal  Accounting
Officer)  in  February  1999.  The  compilation  of  the  financial  information
necessary for the Annual Report has been delayed due to the  resignation  of E&Y
and subsequent recent hiring of D&T as well as the hiring of the Chief Financial
Officer. As a result of such recent hirings, the Chief Financial Officer and D&T
need additional  time to prepare the financial  statements to be included in the
Annual Report.

        The effects of these changes were compounded when, in March 1999, during
the year-end audit, a person with substantial  responsibility in the preparation
of the Company's financial  statements (and knowledge of the Company's financial
affairs  occurring  prior to the hiring of the Chief  Financial  Officer)  had a
heart attack and subsequent  multiple bypass surgery.  As a result,  the Company
has been further  delayed in completing its financial  statements to be included
in the Annual  Report.  However,  the Company will file the Annual Report within
the time prescribed by Rule 12b-25.


                                  Attachment II

The Company has  experienced a significant  change in results of operations from
the  corresponding  period for the last  fiscal  year  related to the  following
items:

The Company has been reducing its human, and other, resources to reduce expenses
while focusing its research and  development  efforts.  To this end, the Company
has  reduced  its R&D  expenses  by  approximately  25% from  last  year and has
significantly  reduced its involvement  with respect to its 50% investment in an
R&D joint venture;

The Company has closed its operation in France; and

The  Company has  substantially  reduced its R&D  operations  in San Diego,  CA,
reduced its G&A  expenses by over $4 million  from last year,  and is moving its
headquarters to Lexington, MA.

Based upon these and other perhaps less significant  factors,  it is anticipated
that  the 1997  loss  applicable  to  common  shares  of  $33.3  milion  will be
materially reduced in 1998.



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission